31st Hemophilia Symposium Hamburg 2000

Epidemiology Inhibitors in Hemophilia Therapy and Monitoring of Bleeds in Acute and Intensive Care Medicine Pediatric Hemostaseology Case Reports

  • Inge Scharrer
  • Wolfgang Schramm
Conference proceedings

Table of contents

  1. Front Matter
    Pages ii-xxx
  2. Johann Lukas Schoenlein Award 2000

    1. I. Scharrer
      Pages 1-4
  3. Epidemiology

    1. Front Matter
      Pages 5-5
    2. W. Schramm, H. Krebs, the GTH Hemophilia Committee
      Pages 7-14
    3. H. K. Hartl, U. Eidher, U. Kunze, P. Arends, J. Falger, N. D. Jones et al.
      Pages 15-19
  4. Inhibitors in Hemophilia

  5. Therapy and Monitoring of Bleeds in Acute- and Intensive-Care-Medicine

    1. Front Matter
      Pages 53-53
    2. A. Calatzis, W. Schramm, M. Spannagl
      Pages 55-66
  6. Pediatric Hemostaseology

  7. Free Lectures

    1. Front Matter
      Pages 99-99
    2. B. Moritz, S. Rogy, S. Tonetta, H. P. Schwarz, H. Ehrlich, the CEPROTIN Study Group
      Pages 101-109
    3. S. Gallistl, G. Cvirn, B. Leschnik, W. Muntean
      Pages 110-113
    4. J. Koscielny, S. Mörsdorf, C. Mrowietz, H. Kiesewetter, U. Budde, U. T. Seyfert et al.
      Pages 114-129
    5. J. Oldenburg, O. El-Maarri, V. Ivaskevicius, S. Rost, B. H. F. Weber, R. Schwaab
      Pages 130-140
  8. Poster: Clinic and Casuistic

    1. Front Matter
      Pages 141-141
    2. H. H. Eickhoff, G. Raderschadt, F. W. Koch, T. Wallny, H.-H. Brackmann
      Pages 143-148
    3. S. Halimeh, H. Pollmann, M. Käse, I. Hörnig-Franz, H. Jürgens, U. Nowak-Göttl
      Pages 149-152
    4. R. Knöfler, J. Wendisch, K. Nemat, G. Siegert, S. Gehrisch, S. Schellong
      Pages 153-158
    5. E. Strasser, Y. Lindemann, B. Neidhardt, I. Scharrer, R. Zimmermann, V. Weisbach et al.
      Pages 159-160
  9. Poster: Hemophilia

    1. Front Matter
      Pages 167-167
    2. G. Ludwig, C. Betz, M. Krause, A. Kurth, L. Hovy, I. Scharrer
      Pages 169-170
    3. M. Şerban, P. Ţepeneu, C. Petrescu, D. Mihailov, C. Jinca, W. Schramm
      Pages 171-178
    4. V. Aumann, G. Lutze, U. Mittler
      Pages 179-180
    5. T. Wallny, L. Hess, A. Seuser, H. H. Brackmann, C. N. Kraft
      Pages 181-185
    6. H. Pollmann, H. Richter, the rFVIII-SQ Study Group
      Pages 186-196
    7. D. Lasovic, G. Tönshoff, M. Fink, A. Rosenstock, A. Ganser, M. Von Depka Prondzinski
      Pages 197-198
    8. G. Schelle, W. Breuer, G. Broil, D. Hohmann
      Pages 199-200
  10. Poster: Hemorrhagic Diathesis

    1. Front Matter
      Pages 201-201
    2. R. Schneppenheim, T. Obser, J. U. Wieding, F. Bergmann, E. Drewke, B. Luxemburg et al.
      Pages 203-207
    3. E. Strasser, R. Zimmermann, B. Neidhardt, B. Manger, I. Scharrer, V. Weisbach et al.
      Pages 208-209
    4. F. Kertzscher, A. Meindl, V. Schuster, U. Sack, M. Koksch, H. Lenk
      Pages 216-218
    5. A. Czwalinna, N. Bartkowiak, B. Canepa, A. Ganser, M. Von Depka Prondzinski
      Pages 225-230
  11. Poster: Thrombophilic Diathesis

    1. Front Matter
      Pages 231-231
    2. B. Maak, S. Hutschenreiter, F. H. Herrmann, K. Wulff, A. Siegemund, W. Christoph
      Pages 233-238
    3. A. Siegemund, T. Siegemund, J. Berrouschot, H. Voigt, M. Koksch
      Pages 239-243
    4. M. Krause, S. Ehrenforth, E. Aygören-Pürsün, G. Ludwig, I. Scharrer
      Pages 244-251
    5. M. Von Lieven, M. Krause, T. Vigh, C. Rabenstein, I. Scharrer
      Pages 252-256
    6. M. Von Lieven, L. Rössig, T. Vigh, C. Rabenstein, I. Scharrer
      Pages 257-261
    7. G. Cvirn, S. Gallistl, M. Köstenberger, J. Kutschera, B. Leschnik, W. Muntean
      Pages 262-272

About these proceedings


Some 23. 5% of all members and patients of treatment centers completed the questionnaire. One striking fact is that participation was highest amongst elderly patients with severe hemophilia, whereas only 12. 2% of family members responded. Evaluation of the results revealed that the majority of participants prefer treat­ ment in a hemophilia treatment center with a high reputation, whereas only 2. 7% consider treatment in a specialized practice to be sufficient. The reasons for that are the necessity of the 24-h-availability of a physician, regular qualified examination of joints and muscles, documentation of product batches, laboratory tests and good cooperation with other faculties. As many as 68. 9% of the patients sometimes travel more than 200 km. What certainly plays a role here is trust in the treatment center and its physicians, for it is noticeable that irrespective of the fact that 74. 3% re­ quested standardized treatment regimens for all treatment centers, only about 20% would change to a nearer center. Treatment with factor concentrates is generally considered to be very safe. That is to say, 58. 1 % regard recombinant products to be very safe, whereas only 24. 3% assume this for plasma products. When compared, there were usually no major differences observed regarding outcome (factor consumption, duration of treat­ ment). Increase in maximum storage temperature (47. 2%) and half-life (73%) were the most frequent answers to the question of what features the products should have.


Hemophilia hemorrhagic diathesis intensive care medicine pediatric hemostasiology thrombophilic diathesis

Editors and affiliations

  • Inge Scharrer
    • 1
  • Wolfgang Schramm
    • 2
  1. 1.Hemophilia Center, Dept. of Internal MedicineUniversity HospitalFrankfurt am MainGermany
  2. 2.Dept. of HemostasiologyUniversity HospitalMünchenGermany

Bibliographic information

  • DOI
  • Copyright Information Springer-Verlag Berlin Heidelberg 2002
  • Publisher Name Springer, Berlin, Heidelberg
  • eBook Packages Springer Book Archive
  • Print ISBN 978-3-540-42131-3
  • Online ISBN 978-3-642-59383-3
  • Buy this book on publisher's site